» Articles » PMID: 11875309

Nitric-oxide-mediated Relaxations in Salt-induced Hypertension: Effect of Chronic Beta1 -selective Receptor Blockade

Overview
Journal J Hypertens
Date 2002 Mar 5
PMID 11875309
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Nebivolol is a new beta1-selective adrenergic receptor antagonist with a direct vasorelaxant effect that involves activation of the l-arginine-nitric oxide (NO) pathway. Therefore, treatment with nebivolol may protect against endothelial injury in hypertension.

Objective: To investigate whether chronic selective beta1-blockade with nebivolol could prevent endothelial dysfunction in salt-induced hypertension, and to compare it with atenolol.

Methods: Dahl salt-sensitive rats were treated for 8 weeks with standard chow or chow containing 4% NaCl alone or in combination with nebivolol (10 mg/kg per day) or atenolol (100 mg/kg per day). Isometric tension was continuously recorded in isolated aorta and small mesenteric arteries. Constitutive NO synthase (cNOS) activity was determined by [3H]citrulline assay.

Results: Chronic salt administration increased systolic blood pressure by 38 +/- 5 mmHg in salt-treated rats as compared with that in control rats. Both nebivolol and atenolol prevented a salt-induced increase in pressure. cNOS activity was significantly decreased by a high-salt diet. The impairment of endothelium-dependent relaxations in response to acetylcholine in salt-treated rats was prevented only by nebivolol, in both large and small arteries. In contrast, the reduced endothelium-independent relaxations and contractions in response to sodium nitroprusside and endothelin-1, respectively, were restored by both drugs. Nebivolol, but not atenolol, restored cNOS activity.

Conclusions: Despite nebivolol and atenolol having the same blood-pressure-decreasing effect, only nebivolol was able to prevent endothelial dysfunction. This study demonstrates for the first time that the acute NO-mediated vasodilatory action of nebivolol is also present during chronic treatment. Hence, nebivolol might become a new therapeutic tool with which to exert vascular protective effects against end-organ damage in conditions associated with NO deficiency.

Citing Articles

Beta-Blockers of Different Generations: Features of Influence on the Disturbances of Myocardial Energy Metabolism in Doxorubicin-Induced Chronic Heart Failure in Rats.

Belenichev I, Goncharov O, Bukhtiyarova N, Kuchkovskyi O, Ryzhenko V, Makyeyeva L Biomedicines. 2024; 12(9).

PMID: 39335471 PMC: 11428500. DOI: 10.3390/biomedicines12091957.


RETRACTED: Investigation of the Potential of Nebivolol Hydrochloride-Loaded Chitosomal Systems for Tissue Regeneration: In Vitro Characterization and In Vivo Assessment.

Elsherif N, Mohsen Al-Mahallawi A, Abdelkhalek A, Shamma R Pharmaceutics. 2021; 13(5).

PMID: 34064916 PMC: 8150897. DOI: 10.3390/pharmaceutics13050700.


Nebivolol is more effective than atenolol for blood pressure variability attenuation and target organ damage prevention in L-NAME hypertensive rats.

Del Mauro J, Prince P, Plantamura Y, Allo M, Parola L, Fernandez Machulsky N Hypertens Res. 2021; 44(7):791-802.

PMID: 33612826 DOI: 10.1038/s41440-021-00630-4.


The Beta-1-Receptor Blocker Nebivolol Elicits Dilation of Cerebral Arteries by Reducing Smooth Muscle [Ca2+]i.

Cseplo P, Vamos Z, Ivic I, Torok O, Toth A, Koller A PLoS One. 2016; 11(10):e0164010.

PMID: 27716772 PMC: 5055296. DOI: 10.1371/journal.pone.0164010.


Changing standard chow diet promotes vascular NOS dysfunction in Dahl S rats.

Spradley F, Ho D, Kang K, Pollock D, Pollock J Am J Physiol Regul Integr Comp Physiol. 2011; 302(1):R150-8.

PMID: 22031779 PMC: 3349380. DOI: 10.1152/ajpregu.00482.2011.